Summary
77 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 52 USD is left as net profit.
- Revenue grew by 45% a year over the last 3 years.
- It earns 39 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- For every 100 USD of bills due within a year it has 38 USD of short-term assets.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
Revenue grew by 15% a year over 5 years. Over the last 3 years it grew by 45% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 30 USD
- Sales and administration 17 USD
- Taxes and other 0.7 USD
- Net profit 52 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 52 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.4 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.